Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 6/20 | 0.75 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.62 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.62 |
| ▸ | CDC25B | P30305 | 2/20 | 0.62 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | SNCA | P37840 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713838 | 1.00 | ALOX15 (0.75) | ALOX15PTPN1PTPN2CDC25BKDM1A | |
| SCHEMBL1713835 | 1.00 | ALOX15 (0.75) | ALOX15PTPN1PTPN2CDC25BKDM1A | |
| SCHEMBL1723909 | 1.00 | ALOX15 (0.75) | ALOX15PTPN1PTPN2CDC25BKDM1A | |
| SCHEMBL23298141 | 1.00 | ALOX15 (0.75) | ALOX15PTPN1PTPN2CDC25BKDM1A | |
| SCHEMBL13835667 | 0.98 | ALOX15 (0.71) | ALOX15PTPN1PTPN2CDC25BKDM1A | |
| SCHEMBL2595100 | 0.98 | ALOX15 (0.71) | ALOX15PTPN1PTPN2CDC25BKDM1A | |
| SCHEMBL2594171 | 0.96 | PTPN1 (0.70) | ALOX15PTPN1PTPN2CDC25BKDM1A | |
| SCHEMBL13835863 | 0.96 | PTPN1 (0.70) | ALOX15PTPN1PTPN2CDC25BKDM1A | |
| SCHEMBL12640681 | 0.90 | ALOX15 (0.80) | ALOX15PTPN1PTPN2CDC25BKDM1A | |
| SCHEMBL13835551 | 0.86 | ALOX15 (0.55) | ALOX15PTPN1PTPN2CDC25BKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157065-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2017-06-08 | — | — | US | claimed |
| US-20130053450-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | EDISON PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | claimed |
| US-8314153-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | claimed |
| EP-2344142-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | Edison Pharmaceuticals, Inc. (US) | 2011-07-20 | — | — | EP | claimed |
| WO-2010030607-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | EDISON PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | WO | claimed |
| US-20100063161-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2010-03-11 | — | — | US | claimed |
| EP-2344142-B1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-3827815-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC Therapeutics, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10736857-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | PTC THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190083419-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2019-03-21 | — | — | US | disclosed |
| US-10105325-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170157065-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9399612-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150239818-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-8969420-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140206772-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2014-07-24 | — | — | US | disclosed |
| US-8653144-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130053450-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | EDISON PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-8314153-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20100063161-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157065-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | ALOX15 845/4885PTPN1 2118/4885PTPN2 2057/4885 |
| US-10105325-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | COMT, ADH4, DDT | ALOX15 845/4885PTPN1 2118/4885PTPN2 2057/4885 |
| US-20140206772-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, DDT, ADH4 | ALOX15 854/4885PTPN1 2108/4885PTPN2 2060/4885 |
| US-20130053450-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | ALOX15 845/4885PTPN1 2118/4885PTPN2 2057/4885 |
| US-20150239818-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | ALOX15 845/4885PTPN1 2118/4885PTPN2 2057/4885 |
| US-20100063161-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | ALOX15 845/4885PTPN1 2118/4885PTPN2 2057/4885 |
| US-10736857-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | COMT, ADH4, DDT | ALOX15 845/4885PTPN1 2118/4885PTPN2 2057/4885 |
| US-20190083419-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | ALOX15 845/4885PTPN1 2118/4885PTPN2 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.